By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


MacuSight, Inc. 

32980 Alvarado-Niles Road
Suite 846
Union City  California  94587  U.S.A.
Phone: 510-400-1440 Fax: 510-400-1441



Start Up

Company News
MacuSight, Inc. Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema 10/21/2009 9:46:26 AM
MacuSight, Inc. Provides Clinical Development Update for Perceiva(TM) Four Phase 2 Clinical Trials in Major Ocular Diseases Fully Enrolled; Data Available in First Half of 2010 9/30/2009 10:37:43 AM
etrials Chosen by MacuSight, Inc. as its EDC and IVR Solutions Provider On Three Ophthalmology Studies 4/16/2009 8:39:55 AM
MacuSight, Inc. Appoints Gerald Wroblewski Vice President of Operations Move Adds Key Manufacturing Expertise as Company Broadly Advances Sirolimus Clinical Development 11/6/2008 10:59:29 AM
Santen Pharmaceutical and MacuSight, Inc. Announce Collaboration and License Agreement for Sirolimus in Ocular Diseases and Conditions; MacuSight to Receive Upfront $50 Million 6/2/2008 8:59:24 AM
MacuSight, Inc. Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration Sirolimus Demonstrates Favorable Safety Profile and Improvements in Visual Acuity 2/25/2008 7:42:28 AM
MacuSight, Inc. Expands Management Team With Appointment of Dr. Joel Naor as Chief Medical Officer 2/20/2008 9:01:41 AM
MacuSight, Inc. Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema 10/1/2007 8:38:49 AM
MacuSight, Inc. Appoints Brian C. Cunningham To Board Of Directors 11/2/2006 11:12:49 AM
MacuSight, Inc. Initiates Wet Age-Related Macular Degeneration Study 10/31/2006 11:13:21 AM